Cyclophosphamide-induced severe acute hepatitis in a rheumatic disease: case-based review.
Rheumatol Int
; 39(2): 377-385, 2019 02.
Article
em En
| MEDLINE
| ID: mdl-30377772
ABSTRACT
In rheumatology practice, the risk of hepatotoxicity from medications, including non-steroidal anti-inflammatory drugs, notably, and methotrexate, sulfasalazine, leflunomide, and azathioprine is highly recognized by the rheumatologists. On the other hand, hepatotoxicity is neither a commonly expected nor a well-known side effect of cyclophosphamide (CYC) which is particularly used for vital organ involvements in systemic lupus erythematosus (SLE) and systemic vasculitis. Here we reported a 19-year-old case of SLE who, while on oral CYC treatment of 100 mg/day, was detected to have asymptomatic liver enzyme elevation and then developed acute hepatitis due to intravenously administered high-dose (1 g) CYC for neuro-lupus. Results of liver biopsy indicated drug-related toxicity. We discussed here with the other, although rare, cases available in the literature with an attempt to highlight the risk of hepatotoxicity and acute hepatitis due to CYC.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ciclofosfamida
/
Doença Hepática Induzida por Substâncias e Drogas
/
Hepatite
/
Lúpus Eritematoso Sistêmico
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article